Chris Heminway, Exec-Chair at Time To ACT, explains why now is the right time for the Group to IPO. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,122.00
Bid: 12,782.00
Ask: 10,914.00
Change: 72.00 (0.60%)
Spread: -1,868.00 (-14.614%)
Open: 11,966.00
High: 12,162.00
Low: 11,966.00
Prev. Close: 12,050.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UK Will Help "Where It Can" With Vaccine As EU Considers Export Ban

Fri, 29th Jan 2021 12:19

(Alliance News) - The UK will aid neighbouring nations with their vaccine supplies "where it can", a government minister has said, as the row between Brussels and AstraZeneca PLC intensified.

Prisons minister Lucy Frazer said the dispute between the EU and the British-Swedish pharmaceutical giant was a "commercial matter", after reports suggested the bloc was considering an export ban to block shipments of vaccines to Britain.

But, in an indication the UK could be willing to share its vaccine supplies, Frazer added: "Our priority is to ensure we vaccinate people in the UK, but of course, where we can help our friends and neighbours, we would do that."

The European Medicines Agency is expected to deliver its verdict on the Oxford-AstraZeneca jab on Friday.

And, according to reports, Brussels could be set to announce powers that would see the shipment of millions of vaccine doses to Britain blocked within days.

The European Commission is said to be considering an export ban in a bid to solve its vaccine supply shortage issues, after member states were forced to pause or delay rollout.

Preventing vaccines made within the bloc from being exported could damage the UK's access to further supplies, particularly to the Belgian-made Pfizer Inc jab.

Brussels has already called for AstraZeneca - which aims to supply two million doses per week to the UK - to send vaccines made at its UK plants across the Channel, after the firm allegedly told the bloc that only a quarter of the 100 million doses it was expecting by March were likely to be delivered.

AstraZeneca on Friday published a redacted version of its contract with the EU, which the bloc said was important for "accountability".

The contract mentions that the firm would use "best reasonable efforts" to use two UK plants as production sites for vaccines destined for the EU.

Despite the argument heating up, Kate Bingham, former chair of the UK Vaccine Taskforce, said she did not think an export ban would materialise.

She told BBC Radio 4's Today programme: "We are interdependent and I don't think that the idea that there are going to be trade barriers is something that we should be considering."

The supply row has spilled over into domestic politics, with the Scottish Government suggesting it could go against Downing Street advice and publish vaccine supply data.

Frazer said the UK government was advising against sharing the information for "security reasons".

But First Minister Nicola Sturgeon, who has come under fire for the speed of inoculation provision, said her administration would "go back to publishing the actual supply figures from next week" so that there was full transparency.

Holyrood ministers were previously forced to change vaccination documents they had published online when the UK Government said setting out how many doses are expected and when, could breach commercial confidentiality.

Frazer said the UK government was being "extremely transparent" but argued that supply data could not be disclosed.

"The government isn't hiding anything at all. My understanding is that it is for security reasons," she told the BBC.

"I think we have been extremely transparent, where it is appropriate to do so, to inform the public about how we are managing the pandemic."

Pressed on what she meant by "security reasons", the junior minister replied: "That is the information I have received."

By Patrick Daly, PA Political Correspondent

source: PA

Copyright 2021 Alliance News Limited. All Rights Reserved.

More News
Today 15:54

Berenberg hikes target price on Astrazeneca

(Sharecast News) - Analysts at Berenberg hiked their target price on drugmaker Astrazeneca from 1,200.0p to 1,300.0p on Tuesday, citing the group was "instilling confidence in the revenues of tomorrow".

Read more
Today 09:51

LONDON BROKER RATINGS: AstraZeneca target raised; Antofagasta lowered

(Alliance News) - The following London-listed shares received analyst recommendations Tuesday morning and Friday:

Read more
6 May 2024 07:46

AstraZeneca completes collaboration and investment deal with Cellectis

(Alliance News) - AstraZeneca PLC on Monday said it has completed an equity investment in clinical-stage biotechnology company Cellectis, first announced in November.

Read more
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.